Background and Objectives: We aimed to describe early real-world visual, refractive, and safety outcomes following implantation of a novel hybrid full range of vision intraocular lens (IOL) in patients undergoing cataract surgery. Materials and Methods: This prospective, single-center, non-randomized clinical study included 50 patients (100 eyes) undergoing bilateral sequential cataract surgery with implantation of the Max Vision™ IOL. Uncorrected and corrected distance visual acuity (UDVA, CDVA) and uncorrected near visual acuity (UNVA) at 32 cm and 40 cm were assessed using logarithmic charts. Spherical equivalent (SE) refraction, intraocular pressure (IOP), and safety outcomes were recorded preoperatively and at postoperative day 1, week 1, and month 1. Preoperative and postoperative values were compared statistically. Results: The mean age was 66.1 ± 7.9 years. At 1 month, mean UDVA improved from 0.58 ± 0.24 to 0.01 ± 0.03 logMAR, and mean CDVA from 0.18 ± 0.20 to −0.001 ± 0.01 logMAR (both p < 0.001). Mean UNVA improved from 0.64 ± 0.18 to 0.19 ± 0.10 logMAR at 32 cm and from 0.61 ± 0.15 to 0.13 ± 0.11 logMAR at 40 cm (both p < 0.001). Mean SE changed from 1.16 ± 1.7 D preoperatively to 0.04 ± 0.4 D at 1 month (p < 0.001). Mean IOP showed a transient increase on postoperative day 1 followed by a reduction at 1 month, without the need for additional hypotensive therapy. No eyes lost two or more lines of CDVA. One posterior capsular rupture occurred without postoperative sequelae. Conclusions: At 1 month after cataract surgery, implantation of the Max Vision™ IOL was associated with improved distance and near visual acuity, early refractive accuracy, and no major short-term safety concerns, under routine clinical conditions.
Valvecchia et al. (2026) studied this question.